Boston scientific announces acquisition of obsidio, inc.

Company to add novel technology cleared for use in peripheral vasculature to interventional oncology and embolization portfolio marlborough, mass. , aug. 15, 2022 /prnewswire/ -- boston scientific corporation (nyse: bsx) today announced the acquisition of obsidio, inc., a privately-held company that has developed the gel embolic material (gem™) technology used for embolization of blood vessels in the peripheral vasculature.
BSX Ratings Summary
BSX Quant Ranking